RxDoctor Payments Data

Eliezer Gomez, MD

Family Medicine · Detroit, MINPI 1124257381

Payments from drug & device makers

$987in general payments, 2019–2025

Across 51 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$265
  • Indivior Inc.$223
  • Orexo US, Inc.$187
  • Redhill Biopharma Inc.$71
  • Phadia US Inc.$59
  • Biohaven Pharmaceutical Holding Company Ltd.$59
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie16$265
Indivior Inc.13$223
Orexo US, Inc.10$187
Redhill Biopharma Inc.1$71
Phadia US Inc.1$59
Biohaven Pharmaceutical Holding Company Ltd.3$59
Pear Therapeutics (US), Inc.2$30
Alkermes, Inc.1$25
RGH Enterprises LLC1$19
Pfizer1$18
Otsuka America Pharmaceutical, Inc.1$17
Braeburn Inc.1$13

How this compares

$987 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$17,216
Medicare patients
98
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl202$24,935
ZubsolvBuprenorphine Hcl/Naloxone Hcl30$8,472
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$7,746
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$5,313
Albuterol Sulfate HfaAlbuterol Sulfate58$1,872
Atorvastatin Calcium132$1,243
Metoprolol Succinate45$835
Diclofenac Sodium51$815
Losartan Potassium74$804
Nifedipine ErNifedipine19$617
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide28$572
Fluticasone Propionate61$516
Lisinopril76$487
Metformin Hcl60$375
Gabapentin37$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Orexo US, Inc.Zubsolv$187$8,47230 claims
Indivior Inc.Suboxone$223$7,74613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →